Cocrystal Pharma (COCP) Receivables (2010 - 2020)

Cocrystal Pharma (COCP) has 10 years of Receivables data on file, last reported at $1.1 million in Q4 2020.

• For the quarter ending Q4 2020, Receivables fell 13.66% year-over-year to $1.1 million; the trailing twelve-month figure through Dec 2020 stood at $1.1 million (down 13.66% YoY), and the FY2020 full-year result was $1.1 million, down 13.66% from the prior year.
• Receivables slipped to $1.1 million in Q4 2020, from $1.2 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $1.8 million in Q2 2019 to a low of $13000.0 in Q2 2016.
• A 4-year average of $1.0 million and a median of $1.2 million in 2020 frame the typical range for Receivables.
• Peak annual rise in Receivables reached 550.99% in 2016, while the deepest fall reached 89.04% in 2016.
• Tracing COCP's Receivables over 4 years: stood at $1.3 million in 2016, then fell by 1.52% to $1.3 million in 2017, then declined by 0.54% to $1.3 million in 2019, then decreased by 13.66% to $1.1 million in 2020.
• Business Quant data shows COCP's Receivables at $1.1 million in Q4 2020, $1.2 million in Q3 2020, and $1.2 million in Q2 2020.